Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study
Year: 2025
Type: article
Study design: Observational Study
Abstract: Managing multiple myeloma (MM) patients receiving advanced (four or more) lines of treatment is a complex challenge. Therefore, real-world data are essential to better understand and address the medical need of this challenging population. We used the EMMY cohort, a French longitudinal real-world study, to describe the characteristics and outcomes of 2127 MM patients receiving advanced-line treatments between 2017 and 2020. A wide variety of treatments were used without a predominant combination showing an evolution over time. Patients exhibited median time to next treatment and overall survival ranging from 7.8 months (95% CI: 6.7-7.8) and 19.4 months (95% CI: 17.4-22.5) in Line 4 (L4) to 4.8 months (95% CI: 3.5-6) and 12.6 months (95% CI: 8.7-16.6) in L8, respectively. The EMMY study provides valuable insights into the real-world application of advanced-line treatments, demonstrating rapid disease progression and poor outcomes in these patients before the novel anti-B-cell maturation antigen (BCMA) directed therapies. These findings highlight the critical need for novel therapies in this population.
DOI: 10.46989/001c.143641
Authors: Titouan Cazaubiel, Olivier Decaux, Bruno Royer, Denis Caillot, Arthur Bobin, Karim Belhadj-Merzoug, Margaret Macro, Laure Vincent, Aurore Perrot, Mohamad Mohty, Lionel Karlin, Caroline Jacquet, Laurent Frenzel, Thomas Chalopin, Cécile Sonntag, Jean Fontan, Sophie Rigaudeau, Cyrille Touzeau, Hélène Demarquette, Abdelaziz Chaib, Clémence Santana, Stéphane Darre, Benoit Bareau, Ronan Garlantézec, Cyrille Hulin
Institutions: Hôpital Cardiologique du Haut-Lévêque, Centre Hospitalier Universitaire de Rennes, Microenvironment and B-cells: Immunopathology, Cell, Differentiation and Cancer, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, CHU Dijon Bourgogne, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Centre Hospitalier Universitaire de Caen Normandie, Hôpital Saint Eloi, Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Université de Toulouse, Hospices Civils de Lyon, Hôpital Lyon Sud, Centre Hospitalier Régional et Universitaire de Nancy, Hôpital Necker-Enfants Malades, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Hôpitaux Universitaires de Strasbourg, Hôpital d'Hautepierre, Hôpital Civil, Strasbourg, Centre Hospitalier Universitaire de Besançon, Université de Versailles Saint-Quentin-en-Yvelines, Nantes Université, Centre Hospitalier Intercommunal Aix-Pertuis, Centre Hospitalier de Valence, Centre Hospitalier d'Arras
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4414309055